Prestige BioPharma Limited (KRX:950210)
South Korea · Delayed Price · Currency is KRW 6,780.00
-60.00 (-0.88%)
Aug 12, 2026, 1:04 PM KST
Prestige BioPharma Market Cap
Prestige BioPharma has a market cap or net worth of 82.21 billion as of August 11, 2026. Its market cap has decreased by -53.37% in one year.
Market Cap
82.21B
Enterprise Value
186.47B
Revenue
16.21B
Ranking
n/a
PE Ratio
n/a
Stock Price
6,780.00
ChartMarket Cap Chart
Since May 28, 2021, Prestige BioPharma's market cap has decreased from 360.58B to 82.21B, a decrease of -77.20%. That is a compound annual growth rate of -24.72%.
| Date | Market Cap | % Change |
|---|---|---|
| Aug 10, 2026 | 79.33B | -48.64% |
| Dec 30, 2025 | 154.45B | -14.96% |
| Dec 30, 2024 | 181.61B | 59.39% |
| Dec 28, 2023 | 113.94B | 29.33% |
| Dec 29, 2022 | 88.10B | -64.84% |
| Dec 30, 2021 | 250.60B | -30.50% |
| May 28, 2021 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Related Stocks
| Company | Market Cap |
|---|---|
| Macrogen | 133.57B |
| Genexine | 123.70B |
| Vaxcell-Bio Therapeutics | 96.98B |
| MedPacto | 94.94B |
| iNtRON Biotechnology | 80.78B |
| CG Invites | 76.43B |
| Amicogen | 72.14B |
| ENCell | 68.05B |